Cells that have stopped dividing but do not disappear accumulate in tissues with age and release substances that provoke inflammation. These are precisely what are called "zombie cells," and they are precisely what a new candidate is aimed at — a synthetic peptide of nine amino acids created with the help of artificial intelligence.
The American company Immorta Bio announced on 12 October 2026 that it had completed the planned preclinical studies of the drug SenoMune-0257. According to the developers, the peptide stimulates the immune system's cytotoxic T cells to recognize and destroy senescent cells without affecting healthy ones. The first human trials are planned to begin before the end of 2026.
Senescent cells arise in response to DNA damage or stress. Normally they should be removed by the immune system, but with age this mechanism weakens. Their accumulation is linked to chronic inflammation, fibrosis, cardiovascular diseases and neurodegeneration. Animal studies show that removing such cells improves physical function, but translating these results to humans remains a difficult task.
Immorta Bio uses an immune approach: instead of directly destroying cells, the drug helps the body recognize them on its own. The company claims that AI helped select candidates from among dozens of variants, and laboratory tests confirmed the selectivity of the action. The peptide is also being developed with an eye toward the formation of immunological memory — the immune system's ability to remember a target for a long time.
Existing senolytics — substances that directly kill senescent cells — often suffer from side effects and toxicity. Personalized cell therapies are expensive and difficult to manufacture. A synthetic peptide, in the company's view, could become a more scalable and cheaper alternative. However, these advantages so far remain theoretical: there are no clinical data on safety and efficacy in humans.
The drug builds on the same company's earlier SenoVax program, in which immune approaches demonstrated suppression of tumors and increased survival in models of cancer and accelerated aging. Nevertheless, the transition from laboratory results to a real patient requires verification: how the peptide will behave in the body, whether it will cause undesirable immune reactions, and whether the effect will persist over time.
Aging is not a single target but an interweaving of many processes: DNA damage, mitochondrial dysfunction, reduced tissue repair. Even the successful removal of "zombie cells" may alleviate individual diseases but will not necessarily slow down the entire aging process. The significance of SenoMune-0257 will be determined not by press releases but by the results of the first phases of clinical trials.
When data on safety and efficacy appear, it will become clear how much the immune peptide is capable of changing the approach to age-associated diseases — or whether it will remain yet another candidate in the long list of promising but as yet unverified developments.
